Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 288 clinical trials
Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT

At the moment there is a lack of data in the setting of oligometastatic PC in particular regarding the interaction between ablative SBRT, ADT and patient's immune system response. The hypothesis underlying this project consists in the idea that the patient's immunological context, RT and ADT may interact in the …

  • 0 views
  • 26 Jan, 2021
  • 1 location
Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma

Many trials that patients with advanced or recurrent indolent lymphoma managed with very low-dose (4Gy) limited-field RT (LD-IFRT) have shown that high response rates and durable remission can be achieved. However, the results of two phase III trials have failed to demonstrate the lasting response rate (RR) with LD-IFRT versus …

  • 7 views
  • 21 Jan, 2021
  • 1 location
Functional Precision Oncology for Metastatic Breast Cancer

This is a pilot study to assess the feasibility of comprehensive genomic characterization and drug screening in metastatic breast cancer. The trial will seek to provide personalized genomic and drug sensitivity information to eligible patients with metastatic breast cancer prior to disease progression on standard treatment. The trial will also …

  • 0 views
  • 24 Feb, 2021
  • 1 location
Safety Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial

aptt
lipase
international normalized ratio
folfirinox
platelet count
  • 1 views
  • 16 Feb, 2021
  • 1 location
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-nave prostate cancer. This trial aims to see if we can improve the way in which prostate …

metastatic prostate cancer
neutrophil count
endocrine therapy
zoledronic acid
adenocarcinoma of prostate
  • 3777 views
  • 26 Jan, 2021
  • 120 locations
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate

  • 247 views
  • 04 Mar, 2021
  • 279 locations
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3K inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic

ct scan
refractory follicular lymphoma
follicular lymphoma
marginal zone lymphoma
ejection fraction
  • 127 views
  • 17 Feb, 2021
  • 144 locations
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or S zary Syndrome (SS)

recently achieved disease control with previous systemic therapy.

mycosis
interferon
systemic therapy
bexarotene
maintenance treatment
  • 898 views
  • 27 Jan, 2021
  • 92 locations
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

) with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.

eczema
atopy
topical agents
lebrikizumab
  • 17 views
  • 02 Mar, 2021
  • 96 locations